Clinical trial · Interventional
Total Intravenous Anesthesia and Recurrence Free Survival
Total IntraVenous AnesthesIa and ReCurrence-free Survival AfTer EsOphageal CanceR SurgerY
NCT04513808CI-TRIAL-00083319recruitingPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 9, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260909-000002
Summary
Brief summary (as posted)
The investigators propose to compare recurrence-free survival in patients having potentially curative (Stages 1-3) surgery for esophageal cancer who will be randomly assigned to propofol-based total intravenous anesthesia or sevoflurane-based balanced general anesthesia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Propofol-based total intravenous anesthesia | Drug | — | UNRESOLVED |
| Sevoflurane intravenous anesthesia | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Propofol-based total intravenous anesthesia
- description
- Propofol-based total intravenous anesthesia. A target-controlled infusion will be set to 2-4 µg/ml plasma concentrations, and varied as clinical necessary.
- interventionNames
- Drug: Propofol-based total intravenous anesthesia
- type
- ACTIVE_COMPARATOR
- label
- Sevoflurane intravenous anesthesia
- description
- Anesthesia will be maintained with sevoflurane, typically at an end-tidal concentration of 0.6-1.0 MAC, but adjusted as clinically necessary
- interventionNames
- Drug: Sevoflurane intravenous anesthesia
Primary outcomes (1)
- measure
- Recurrence-free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Primary esophageal cancer without known extension beyond the esophagus. (i.e. believed to be Tumor Stage 1-3). * Scheduled for potentially curative esophageal cancer surgery. * Written informed consent, including willingness to be randomized to intravenous versus volatile anesthesia. Exclusion Criteria: * Previous surgery for esophageal cancer (except diagnostic biopsies) Age \<18 or \>85 years old. * ASA Physical Status ≥4. * Any contraindication to propofol or sevoflurane. * Other cancer not believed by the attending surgeon to be in long-term remission. * Systemic disease believed by the attending surgeon to present ≥25% two- year mortality.
References
Publications (0)
Data not yet available
No reference posted for this study.